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Abstract
 
We have recently described that sustained 
 
Plasmodium falciparum
 
 growth could be obtained
 
 
 
in
immunodeficient mice. We now report the potential of this new mouse model by assaying the
effect of the passive transfer of antibodies (Abs) which in humans have had a well-established
effect.
Our results show that the total African adult hyperimmune
 
 
 
immunoglobulin Gs (HI-IgGs)
strongly reduce
 
 P. falciparum 
 
parasitemia similarly to that reported in humans, but only when
mice are concomitantly reconstituted with human monocytes (HuMNs). In contrast, neither
 
HI-IgGs nor HuMNs alone had any direct effect upon parasitemia. We assessed
 
 
 
the in vivo ef-
 
fect of epitope-specific human Abs
 
 
 
affinity-purified on peptides derived either from the ring
erythrocyte surface antigen (RESA) or the merozoite surface protein 3 (MSP3). The inocula-
tion of low concentrations of anti-synthetic peptide from MSP3, but not of anti-RESA Abs,
consistently suppressed 
 
P. falciparum 
 
in the presence of HuMNs. Parasitemia decrease was
stronger and faster than that observed using HI-IgGs and as fast as that induced by chloroquine.
Our observations demonstrate that this mouse model is of great value to evaluate the protective
effect of different Abs with distinct specificity in the same animal, a step hardly accessible and
therefore never performed before in humans.
Key words: mouse model • protective immunity • antibody-dependent cellular inhibition • 
merozoite surface protein 3 • ring erythrocyte surface antigen
 
Introduction
 
Malaria due to 
 
Plasmodium falciparum
 
 causes the highest
mortality in individuals living in endemic countries. The
development of weapons, particularly vaccines, to fight this
major public health problem has been severely hampered
by the lack of a suitable in vivo model. Only a very small
number of primate species are receptive to 
 
P. falciparum
 
,
which scarcity and cost preclude any widespread use (1–3).
Animal models for falciparum malaria in immunodefi-
cient, chimerical mice have been described recently (4–6).
We used mice bearing the mutations beige, X-linked im-
munodeficient, and nude (BXN) affecting the T and B cell
functions. In this model, the partial depletion of circulating
and tissue phagocytes was crucial to the successful grafting
of human red blood cells (HuRBCs) and to the develop-
ment of the erythrocytic cycle of 
 
P. falciparum 
 
(4). After our
initial report, further progress was made in controlling
mouse macrophages which resulted in obtaining consis-
tently long-lasting, stable parasitemias. In the BXN mice,
the morphology of the 
 
P. falciparum
 
 parasite and the re-
sponses to currently employed antimalarial drugs were sim-
ilar to those observed in humans (Moreno, A., E. Badell,
N. van Rooijen, and P. Druilhe, manuscript submitted for
publication), therefore confirming the validity of this in
vivo 
 
P. falciparum
 
 model.
In view of the need to improve the understanding of
host–parasite interactions for vaccine development, we
evaluated the relevance of this 
 
P. falciparum
 
 mouse model
for the analysis of the effects of different components of the
human immune system on the parasite. There is consider-
able in vivo evidence that the IgG constitutes an efficient
protective arm of the immune system against 
 
P. falciparum
 
erythrocytic stages in humans (7–9). Therefore, passive
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transfer experiments were carried out to determine the ef-
fect of total African IgG or affinity-purified Abs against two
vaccine candidates, merozoite surface protein 3 (MSP3)
and ring erythrocyte surface antigen (RESA), upon the
growth of
 
 P. falciparum
 
 in these mice.
 
Materials and Methods
 
Immunomodulation of Innate Immunity in BXN Mice.
 
6–8-wk-
old male BXN mice were used. They were purchased from
Charles River Laboratories, kept and manipulated under patho-
gen-free conditions. The protocol of immunomodulation de-
scribed below represents a major improvement to our earlier pro-
tocol (4). The numbers of tissue macrophages in the peritoneum,
spleen, and liver were reduced by intraperitoneal injection of 0.2
ml of dichloromethylenediphosphonate (Cl
 
2
 
MDP) encapsulated
in liposomes (10) every 4–5 d. Cl
 
2
 
MDP was a gift of Roche Di-
agnostics (Mannheim, Germany). The increase in the number of
blood polymorphonuclear neutrophils (PMNs) was controlled by
intraperitoneal injections, every 3–4 d, of 300 
 
m
 
g of anti-PMN
monoclonal Ab, NIMP-R14 (11), purified from a hybridoma
provided by Dr. M. Strath (National Institute for Medical Re-
search, London, UK). We observed that mouse monocyte (MN)
numbers were maintained at physiological levels in the period
when these injections were made.
 
Grafting of Human Parasitized Red Blood Cells.
 
Human AB
 
1
 
blood was collected on citrate phosphate dextrose (Macopharma)
from donors with no previous history of malaria and centrifuged
at 600 
 
g
 
 for 10 min at 20
 
8
 
C. The white blood cells (buffy coat)
were removed, and the packed red blood cells were suspended in
sodium adenine glucose mannitol (Macopharma) and kept at 4
 
8
 
C
for 
 
,
 
30 d. Before use, HuRBCs were washed three times at 600 
 
g
 
with RPMI 1640 (GIBCO BRL). We used the 
 
P. falciparum
 
African strains, NF54 and FCIP150, cultured in RPMI 1640 sup-
plemented with 1 mg of hypoxanthine/liter
 
 
 
(RPMI-Hyp) and
0.5% Albumax (GIBCO BRL). Synchronized ring forms (para-
sitemia between 1 and 3%) were obtained after reinvasion by flo-
tation on plasmagel (Bellon) (12), and were washed for 5 min at
400 
 
g
 
 in RPMI-Hyp. They were then resuspended in RPMI-
Hyp at 50% hematocrit, and 2 ml of this suspension was injected
intraperitoneally into each mouse on day 0. Afterwards, 2 ml of
noninfected HuRBCs as described above was injected intraperi-
toneally at 3–4-d intervals in each mouse. The parasitemia was
monitored by daily Giemsa-stained, thin blood films drawn from
the tail vein. These paratized HuRBCs are hereafter referred to as
 
P.f.
 
-HuRBCs.
 
Passive Transfer Experiments in BXN Mice Grafted with P.f.-HuR-
BCs.
 
Total human peripheral blood mononuclear cells (HuPB-
MCs) from normal blood donors were isolated by Ficoll-hypaque
(13) and washed twice with HBSS buffered with 0.01 M of
Hepes (GIBCO BRL). Human monocytes (HuMNs) were ac-
tively selected by CD14
 
1
 
 magnetic beads using the MACS kit for
magnetic cell sorting, according to the manufacturer’s instructions
(Miltenyi Biotec). This procedure allowed us to obtain 99% pure
MN preparations with a viability >95%. The purity and viability
of cellular suspension were verified by nonspecific esterase stain-
ing (14) and Trypan blue, respectively. Either 3
 
 3 
 
10
 
7
 
 HuPBMCs
or 3
 
 3 
 
10
 
6
 
 purified HuMNs suspended in 1 ml of RPMI medium
were injected intraperitoneally in each mouse. These BXN mice
are hereafter referred to as
 
 P.f.
 
-HuRBC-BXN mice.
A pool of human hyperimmune IgG was recently obtained
from 200 sera collected from protected adults living in a hyperen-
demic area of the Ivory Coast in Africa (HI-IgG), essentially as
described by Bouharoun-Tayoun et al. (15) except that the purifi-
cation of IgG was made by ion-exchange chromatography on
columns Q fast flow and SP sepharose fast flow (Amersham Phar-
macia Biotech; reference 16). These subjects are referred to as
protected since they have reached a state of clinical immunity to
malaria. For passive transfer experiments, 6 mg of total HI-IgGs
was injected per mouse, which corresponds to a dose of 200 mg/
kg, previously shown to be effective in humans (9). Sampling of
mice at regular intervals after IgG transfer and the determination
of Ab concentrations by ELISA showed that mouse catabolism led
to a progressive disappearance of the transferred Abs within 7 d.
To prepare anti-MSP3b and anti-RESA peptide Abs, the
MSP3b with an additional COOH-terminal cysteine (MSP3b-
Cys) peptide (sequence AKEASSYDYILGWEFGGGVPEHK-
KEEN) or the RESA peptide (sequence H-[EENVEHDA]
 
2
 
-
[EENV]
 
2
 
-OH) were bound to a Sulfolink column (Pierce
Figure 1. In vivo transfer of either HI-IgGs or HuPBMCs in P.f.-
HuRBC-BXN mice. Course of P. falciparum parasitemia in P.f.-HuRBC-
BXN mice undergoing the complementary immunomodulation protocol,
injected intraperitoneally on day 0 with P. falciparum–infected HuRBCs.
Noninfected HuRBCs were injected subsequently at 3–4-d intervals. (A)
Shown is the mean 6 SD from the parasitemia in seven representative
BXN mice. (B) Mean parasitemia in three P.f.-HuRBC-BXN mice after
intraperitoneal injection of HI-IgGs at a dose of 200 mg/kg. (C) Mean
parasitemia in five P.f.-HuRBC-BXN mice after intraperitoneal injection
of 30 3 106 HuPBMCs/mouse. Arrows, day of injection. 
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Chemical Co.), according to the manufacturer’s instructions. 28
mg of total HI-IgGs was then loaded on these columns and ran at
a rate of 1 ml/10 min at 4
 
8
 
C in a closed circuit for 24 h. After
washing with PBS for 18 h at the same rate and temperature, a
specific IgG was eluted from the column using a 0.2 M glycine
solution (Sigma-Aldrich), with a pH 2.5 buffer. 1-ml fractions
were collected, and the pH was immediately adjusted to 5.0 with
2 M Tris-NaOH (Sigma-Aldrich). To preserve the biological ac-
tivity of the Abs, BSA was added at 2 mg/ml (Boehringer). The
reactivity of each fraction against the peptide was monitored by
ELISA, and those containing specific Abs were pooled and con-
centrated to 500 
 
m
 
l using a Centricon 30 (Millipore). The Abs
were then dialyzed against PBS and RPMI 1640 for 24 h, steril-
ized on 0.220-
 
m
 
m Millex filters (Millipore), and stored at 4
 
8
 
C
until use.
For passive transfer experiments, the IFA titer of the immu-
nopurified anti-MSP3 or anti-RESA Abs was determined at the
time of injection, and 250 
 
m
 
l/mice of these solutions was injected
intraperitoneally.
 
Titration of Purified Abs on Native Protein.
 
The titer of each
peptide-specific Ab preparation was determined by a 30-min in-
cubation of serial twofold dilutions on acetone-fixed thin blood
smears of 
 
P. falciparum
 
 (NF54 strain) containing either a majority
of mature schizonts for anti-MSP3 Abs or a majority of ring
forms for anti-RESA Abs. After washing in PBS, the slides were
incubated with an anti–human, FITC-labeled secondary Ab
(Biosys) diluted 1:200 in PBS supplemented with Evan’s blue,
1:5,000 (Sigma-Aldrich). The titers obtained of each Ab suspen-
sion after concentration to a volume of 500 
 
m
 
l were: 1:200 or 1:400
for anti-MSP3 (depending on certain preparations) and 1:1,200
for anti-RESA Abs.
 
ELISA.
 
MSP3 or RESA peptide solutions at a concentration
of 5 
 
m
 
g/ml in PBS, pH 7.4, were incubated overnight (50 
 
m
 
l/
well) at 4
 
8
 
C in Maxisorb plates (Nunc). A solution of 2.5%
skimmed milk in PBS was then added, and the plates were incu-
bated for 2 h at room temperature. Aliquots of each fraction ob-
tained in the immunopurification process of anti-MSP3 or anti-
RESA Abs were diluted to 1:2 in PBS containing 1.25%
skimmed milk. Afterwards, 50 
 
m
 
l of these dilutions was incubated
in the coated plates for 1 h at room temperature, followed by an
incubation of anti–human goat Fc
 
g
 
 fraction of IgG Abs conju-
gated to peroxidase (Biosys) diluted 1:2,000 in PBS containing
1.25% skimmed milk. After each incubation step, five washes
were done using PBS containing 0.1% Tween 20 (Bio-Rad Lab-
oratories). A solution containing 1 mg/ml Ortho Phenylene Di-
amine (Sigma-Aldrich) and l 
 
m
 
l/ml 30% H
 
2
 
O
 
2
 
 in 0.1 M citrate
buffer, pH 7.3, was used to reveal the enzymatic reaction. The
optical density was measured at 450 nm using a Titertek Multi-
skan Mcc340 apparatus.
 
Results and Discussion
 
HI-IgGs or HuMNs Alone Have No Direct Effect In Vivo on
P. falciparum.
 
Results obtained using the modified scheme
of modulation of innate immunity in immunocompromised
BXN mice are summarized in Fig. 1. In these mice, 
 
P. falci-
parum
 
 multiplication was obtained in a long-lasting (up to 4
mo), stable manner in HuRBCs. The range of parasitemias
(0.1–5%) was lower than in South American primates (2,
17, 18) but closer to that usually observed in humans (19,
20), with moderate daily variations similar to those seen in
untreated patients (20, 21). The level and consistency of the
Figure 2. In vivo transfer of HI-IgGs together with HuPBMCs (A and
B) or MNs (C and D) in P.f.-HuRBC-BXN mice. Individual parasitemia
in two out of four mice injected sequentially with either 200 mg/kg of
HI-IgGs at day 9, followed 6 d later by HuPBMCs (3 3 107) (A) or the
same in the reverse order on days 6 and 9, respectively (B). Arrows show
treatment days. In mouse A (but not in mouse B) an additional dose of
100 mg/kg of HI-IgGs was added because of the longer delay between
the two treatments and the fast catabolism of human IgGs. Two other
mice undergoing the same protocol showed the same effect on the course
of P. falciparum parasitemia. C and D show the individual parasitemia of
two out of four mice undergoing the same protocol except that purified
HuMNs were used at a rate of 3 3 106 ntraperitoneally instead of total
PBMCs, together with 200 mg/kg of HI-IgGs. In mouse D, only the ini-
tial IgG injection was of 200mg/kg and the further two were of 100 mg/
kg. In two other mice, not shown in the figure, receiving IgG and/or
MNs on days 10 and 15, or 16 and 22, respectively, the decrease of para-
sitemia occurred over 4 d after the first combined injection. Only mouse
D showed a partial response to treatment. 1, one or two parasites ob-
served in thin blood smears; 2, parasites no longer detectable in thin
blood smears. 
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IgGs alone and then received HuPBMCs plus HI-IgGs 6 d
later (Fig. 2 A). In another infected mouse, HuPBMCs
were first injected and Hu-IgG was only added 3 d later
(Fig. 2 B). When initially added alone, the two immune
components showed no inhibitory effect on the para-
sitemia, but when present together a strong reduction of
parasitemia was observed. Duplicate results were obtained
in two other mice treated in the same fashion (data not
shown). The role of MNs in parasite growth inhibition was
demonstrated by injecting enriched human MNs, instead
of HuPBMCs, together with HI-IgGs. A similar inhibitory
parasitemia in our model were thus considered suitable to
envisage studies of the role of immune effectors.
The injection of HI-IgGs, in similar quantities (200 mg/
kg) to those used in passive transfer experiments in humans
(9), surprisingly induced no significant change in the course
of parasitemias in the 
 
P.f.
 
-HuRBC-BXN mice (Fig. 1 B).
These results were consistent among five similarly treated
mice, despite the fact that substantial levels of human Abs
could indeed be detected by ELISA (up to 8 d in all) in the
injected mice (data not shown).
These observations differed from those made after the
passive transfer in immunocompetent humans (9) but were
reminiscent of those obtained under in vitro conditions
(15, 22). We had previously shown that HI-IgGs alone had
no effect on 
 
P. falciparum
 
 in vitro, but a potent inhibitory
effect is obtained when IgGs cooperate with blood MNs.
This Ab-dependent, cell-mediated cytotoxicity-like coop-
eration was termed Ab-dependent cellular inhibition
(ADCI [15, 23, 24]). The current observation suggested
that in our model, MNs from treated mice were unable to
cooperate with human IgGs in an ADCI fashion. This
raised the possibility that MNs of human origin are re-
quired. We first investigated the effect of HuMNs alone,
since it has been reported that MNs
 
 
 
can nonspecifically in-
hibit parasite growth (25). We injected either total HuPB-
MCs (3
 
 3 
 
10
 
7
 
) or purified HuMNs (3
 
 3 
 
10
 
6
 
) into infected
mice. The injection of 3
 
 3 
 
10
 
7
 
 HuPBMCs resulted in the
detection by FACS
 
®
 
 of 800 HuMNs/
 
m
 
l of mouse blood
(data not shown), i.e., close to physiological levels. As
shown in Fig. 1 C and Fig. 2, B and C, the injection of ei-
ther HuPBMCs or purified MNs had no direct effect on
the course of parasitemia at the concentrations employed.
These results were consistently obtained in a total of eight
different mice.
 
HI-IgGs and HuMNs Are Needed to Control P. falciparum
In Vivo in Mice.
 
The medium-grade stable parasitemias
that can be obtained in immunocompromised mice allow
one to perform sequential studies with several immune ef-
fectors. One infected mouse was first injected with HI-
 
Table I.
 
Specificity of Immunopurified Abs against MSP3 and 
RESA Peptides Detected by IFA and ELISA
 
IFA ELISA
Abs Schizonts Rings MSP3 RESA
N-IgG
 
(
 
2
 
)(
 
2) 58 62
HI-IgG 1/12,000 1/12,000 908 (16) 859 (14)
MSP3b-IgG 1/400 (2) 942 (16) 39 (0.6)
RESA-IgG (2) 1/1,200 37 (0.6) 821 (13)
IFA was performed on slides containing a high percentage of ring forms
for anti–RESA-IgG and a high percentage of schizonts for anti–MSP3b-
IgG. The ratio (in parentheses) was calculated by dividing the optical
density of each IgG preparation by the optical density of normal human
IgG (N-IgG) against each peptide.
Figure 3. In vivo transfer of anti-MSP3b peptide Abs with HuMNs in
P.f.-HuRBC-BXN mice. (A) Course of parasitemia in a mouse receiving
a single injection of HuMNs (3 3 106). (B) Parasitemia in a mouse re-
ceiving a single injection of anti-MSP3b peptide–specific human Abs (at a
rate of 250 ml of a solution titrating at 1:200 by IFA). (C and D) Course
of parasitemia in two mice receiving first HuMNs (3 3 106) and thereaf-
ter the anti-MSP3b Abs (250 ml) together with an additional dose of
HuMNs (3 3 106). 1 and 2, presence or absence of few residual parasites
in thin blood smears. Arrows, day of injection.1657 Badell et al. Brief Definitive Report
effect on parasite growth was observed (Fig. 2, C and D) in
these and duplicate experiments, irrespective of the order
of injection. The reduction in parasitemia observed in
mice, although strong, was nonetheless subcurative, i.e., a
low grade parasitemia persisted for several days. This was
also the case in passive transfers in humans (9).
Immunopurified Anti-MSP3, but Not Anti-RESA Abs, In-
hibit Parasite Growth. The results obtained using total HI-
IgGs and HuMNs established the model potential for assay-
ing the effect of Abs and led us to evaluate the protective
effect of Abs with defined specificity, a step hardly accessi-
ble and therefore never performed before in humans. To
this end, we affinity-purified Abs from the HI-IgG pool on
epitopic peptides. We chose MSP3b and the RESA pep-
tide, derived from the two vaccine candidates MSP3 and
RESA, respectively. Before the passive transfers, the speci-
ficity and titers of the purified Abs were assessed against
both the original peptides and the native parasite antigens.
Both sets of Abs reacted specifically at 1:400 dilution for
the anti-MSP3 Abs and 1:1,200 for the anti-RESA Abs
(Table I).
The in vivo effect of the two purified Abs was investi-
gated using the sequential procedure described above,
where each mouse served as its own control. The transfer
of anti-MSP3 Ab or purified HuMNs alone had no effect
on P. falciparum parasitemia (Fig. 3, A and B). However,
the addition of HuMNs followed 3 d later by the injection
of the specific Ab induced a fast, strong, and consistent de-
crease in parasitemia (Fig. 3, C and D). On average, the de-
crease (.10-fold/48 h) was stronger and faster than that
observed with total HI-IgG (Fig. 2 C), and as fast as that
observed when using chloroquine either in P.f.-HuRBC-
BXN mice (Moreno, A., E. Badell, N. van Rooijen, and
P. Druilhe, manuscript submitted for publication) or in hu-
mans (26). These results were reproduced in six different
mice, in three distinct experiments using three separate
batches of Abs and HuMNs. By contrast, the parasitemia in
two other mice remained unchanged when a similar course
of injections was performed with anti-RESA Abs and
HuMNs (Fig. 4, A and B). However, parasite numbers
dropped drastically when the same mice were further in-
jected with anti-MSP3 Abs and HuMNs 3–4 d later. Fi-
nally, and in contrast to results obtained with HI-IgG, five
out of six mice completely cleared the parasitemia.
It is striking that such a profound, biological effect was
obtained using a very minor subset of all antimalarial Abs
present in the hyperimmune serum. Nonetheless, there is
convergence with data obtained by other approaches. The
strong effect of low amounts of anti-MSP3 Abs in BXN
mice is in keeping with indications previously gathered un-
der in vitro conditions (27); also, recently obtained immu-
noepidemiological data further corroborate the protective
role of low amounts of anti-MSP3b peptide IgG3 Abs
(Roussilhon, C., C. Oeuvray, J.L. Perignon, and P.
Druilhe, manuscript in preparation). The lack of inhibition
obtained with anti-RESA Abs clearly does not rule out a
role for this molecule, particularly since these were purified
on a short peptide.
Fig. 5 shows the rate of parasitemia decrease in two
groups of six mice treated either by total African HI-IgGs
or affinity-purified anti-MSP3 Abs, with both cases receiv-
ing human MNs. Anti-MSP3b peptide Abs achieved a fast
and total clearance of parasites, whereas HI-IgG induced a
slower rate of parasite clearance (P  ,  0.05), leaving a
chronic, low-grade parasitemia. It should be noted that the
titer of affinity-purified, anti-MSP3b Abs was adjusted to
be the same as that in total HI-IgGs (Table I), i.e., total HI-
IgGs contained the same amounts of anti-MSP3b Abs that
Figure 4. Sequential effect of anti-RESA and anti-MSP3b Abs. Course
of parasitemia in two P.f.-HuRBC-BXN mice receiving sequential treat-
ment first by HuMNs, then by HuMNs together with anti-RESA pep-
tide Abs (250 ml of a solution with a titer of 1:2,000 by IFA), and fol-
lowed by HuMNs together with anti-MSP3b peptide Abs (250 ml, IFA 1:
200). The arrows show the days at which treatment was administered. 2,
absence of residual parasites in thin blood smears.
Figure 5. Decrease of parasitemia in HI-IgG– and anti-MSP3b–treated
mice. Comparison between the mean decrease in parasitemias (6 SD) in
two groups of six mice, one treated by total African HI-IgGs (h), the
other by affinity-purified anti-MSP3 Abs (j). In both groups, HuMNs
and Abs were injected on day 0. Note that the percentage of reduction of
parasitemia is shown as a logarithmic scale.1658 Specific Inhibition of Plasmodium falciparum in Immunocompromised Mice
were present in the purified preparation. This observation
indirectly implies that other Abs present in HI-IgG might
block the inhibitory effect of anti-MSP3 Abs. Such a
blocking effect is reminiscent of that observed with anti-
MSP1 Abs (28), or could also be related to noncytophilic
Abs directed to other merozoite surface antigens, resulting
in steric hindrance. This observation has important impli-
cations for vaccine development, as it can be taken as an in-
dication that immunization by selected malarial antigens
may elicit stronger protective responses than those resulting
from exposure to all malarial proteins. In other words, the
immunization by molecules which are proven targets of
protective mechanisms may lead to induce a stronger pro-
tection than that developed by natural exposure.
For this type of study, the in vivo BXN model offers
several significant advantages over in vitro assays: (a) in
mice, the liver, kidney, and pulmonary functions provide a
constant physiological environment with optimally regu-
lated pH, electrolyte balance, glucose regulation, and nutri-
ent supply which are known to vary in vitro, and toxic
substances produced by the parasite (e.g., lactate, pigment)
are efficiently scavenged by the mouse; (b) serum lipids
preserve the integrity of human cell membranes whereas
erythrocytes are fragilized in vitro (29); (c) in vitro MN ad-
herence to plastic triggers their fast differentiation into
macrophages which are inefficient in ADCI (30), which
was not seen in mice (data not shown); and (d) in static cul-
tures, inhibitory effectors produced by HuMNs (24) are in
direct contact with P. falciparum. The fact that parasite
growth inhibition is seen in the mice, despite the dilution
of these monokines by the circulation, indicates that they
are indeed highly potent.
In conclusion, the novel P. falciparum mouse model can
now be employed for rapid in vivo investigations of the
protective role of antigen-specific Abs. It allows one to em-
ploy very small amounts of defined Abs to investigate the
protective role of a given antigen expressed by malarial par-
asites. In this respect, it stands aside from current strategies
relying on the immunization of rare and costly primates
susceptible to P. falciparum. Moreover, the two approaches
differ also in their concept: Abs induced by artificial immu-
nization may differ in their protective effect from naturally
acquired Abs due to differences in their fine epitope speci-
ficity or isotype profile. Given the very large number of
malarial molecules which are potential vaccine candidates,
the P. falciparum mouse model could provide an efficient
means to select those most suitable to initiate vaccine de-
velopment.
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